68 results about "Receptor subunit" patented technology

Provided are methods and compositions for treating and / or preventing C. difficile infections, particularly recurring C. difficile infections. The compositions for use in treating and / or preventing C. difficile infections include in some embodiments at least one agent that inhibits an alpha 2 adrenergic receptor, and the presently disclosed methods include administering at least one such composition to a subject in need thereof, optionally in combination with other therapeutically active agents including but not limited to an enhancer of an IL-13 biological activity, optionally an IL-13 peptide or a fragment or homolog thereof; an interleukin-13 receptor subunit alpha-2 (IL-13Ra2) inhibitor; an enhancer of an Interleukin-33 (IL-33) biological activity, optionally an IL-33 polypeptide or a biologically active fragment or homolog thereof; or any combination thereof.

Provided are compositions and method for prophylaxis and / or therapy of hearing loss or related dysfunctions, including but not limited to tinnitus, that could be ameliorated by restoring central nervous system inhibitory synapses. The compositions include polynucleotides and viral vectors that are used to express at least one GABA receptor component which may be a GABAA receptor alpha 1 subunit or GABAR receptor Ib subunit. Expression of the GABA receptor may be under control of a CaMKII promoter.

Disclosed are novel methods of assessing transplant rejection status in a transplant recipient, such as a kidney transplant recipient. The diagnostic method identifies stable subjects, subjects undergoing cell mediated rejection processes, and subjects undergoing antibody mediated rejection processes using measurement of TCR subunit repertoire diversity. The proportion of unique TCR alpha and beta subunit sequences to total unique TCR subunit sequences (total sequences for alpha, beta, delta, and gamma subunits) provides a diagnostic measure that can identify stable subjects, subjects undergoing cell mediated rejection processes, and subjects undergoing antibody mediated rejection processes. Methods of treatment include administration of a suitable treatment if antibody mediated rejection or cell mediated rejection is detected.

The present application discloses an IL-2 derivative, by introducing at least one cysteine residue on the basis of wild type IL-2, partially or completely closing the binding plane of the IL-2 derivative with the alpha receptor subunit, while basically retaining the affinity to the beta and gamma receptor subunit complex.

The invention belongs to the technical field of in-vitro diagnosis and anesthesia monitoring. The invention discloses a serum protein marker combination for evaluating anesthesia depth and application of the serum protein marker combination. The composition is composed of orexin, S100 calcium binding protein B, C reactive protein and gamma-aminobutyric acid A type receptor alpha1 subunit, and can synergistically reflect the anesthesia sedation state from multiple dimensions. The invention also provides a detection kit containing the marker and application of the detection kit in evaluation of anesthesia depth. The combination has the advantages of being high in accuracy, objective, stable and easy to detect, can serve as an effective supplementary tool of an existing nerve electrophysiology monitoring technology, and provides a new reference means for intraoperative sedation depth monitoring and precise anesthesia management.

Provided are antibodies and antigen binding fragments thereof that bind to human interleukin-11 receptor subunit α (IL-11Rα) and related compositions, which may be used in any of a variety of therapeutic or diagnostic methods, including the treatment or diagnosis of cancers, inflammatory diseases, autoimmune diseases, and others.

Disclosed is a polypeptide dimeric protein containing two monomers, each of which contains an extracellular domain (FcεRIa-ECD) of an alpha subunit of an IgE Fc receptor. The dimeric protein has advantages that an excellent binding ability to IgE is exhibited as compared with a conventional therapeutic agent containing an anti-IgE antibody, and less other side effects are exhibited due to lack of ADCC and CDC functions. Thus, the dimeric protein can be applied to a medical product for treating or preventing an IgE-mediated allergic disease.

The present invention belongs to the field of medicinal chemistry technology, specifically relating to GluA2 AMPAR endocytosis-blocking transmembrane cyclic peptides and their applications. The present invention is based on the nine active amino acid sequence (GluA2-3Y) at the end of the AMPA receptor GluA2 subunit, undergoing structural modification and engineering. A hydrophobic group is attached to the N-terminus of the peptide, and amino acids at different positions in the peptide sequence are replaced with two cysteines according to a specific pattern. The sulfhydryl groups on the cysteines are then linked using a chemical linker to partially cyclicize the peptide sequence, thereby stabilizing the peptide sequence conformation, enhancing the transmembrane ability of the modified peptide, and improving the stability of the peptide sequence.

The present invention relates to the resolution of interleukin mimetics and their uses. Disclosed are conditionally active receptor agonists that bind to an IL-2 receptor [beta] [gamma] c heterodimer (IL-2R [beta] [gamma] c), an IL-4 receptor [alpha] [gamma] c heterodimer (IL-4R [alpha] [gamma] c), or an IL-13 receptor [alpha] subunit (IL-13R [alpha]) upon activation, as well as components of the conditionally active receptor agonists and methods for using the conditionally active receptor agonists.

Engineered synthetic signaling molecules, herein termed "trikines", are provided. Trikines are genetically engineered, tri-specific ligands of cell surface receptors, where the trikine specifically binds at high affinity to the extracellular domains of three different cell surface receptor polypeptides. In some embodiments, generation of a receptor multimer by binding to a trikine results in intracellular trans-phosphorylation of receptor subunits. In some embodiments trikines modulate STAT signaling that results from the receptor binding and mutimerization.

The present invention provides compounds of formula (I) and / or salts thereof and / or biologically active metabolites thereof and / or prodrugs thereof and / or solvates thereof and / or hydrates thereof and / or polymorphs thereof having affinity and selectivity for the gamma-aminobutyric acid A receptor subunit alpha 5 and act as GABAA α5 positive allosteric modulators, thereby useful in the treatment or prevention of diseases related to the GABAA α5 receptor, process for the preparation and intermediates of the preparation process thereof, pharmaceutical compositions comprising them alone or in combination with one or more other active ingredients and their use as medicaments.

The present invention provides compounds of formula (I) and / or salt thereof and / or biologically active metabolite thereof and / or prodrug thereof and / or solvate thereof and / or hydrate thereof and / or polymorph thereof having affinity and selectivity for the gamma-aminobutyric acid A receptor subunit alpha 5 and act as GABAA α5 negative allosteric modulators, thereby useful in the treatment or prevention of diseases related to the GABAA α5 receptor, process for the preparation and intermediates of the preparation process thereof, pharmaceutical compositions comprising them alone or in combination with one or more other active ingredients and their use as medicaments.

Provided are binding molecules with at least one interleukin-31 (IL-31) receptor subunit alpha-antigen-binding domain (IL-31RA-antigen-bindingdomain)capable of inhibiting IL-31activity,compositions of such binding molecules for treating IL-31-mediated disorders, uses of such binding molecules as medicaments for treating IL-31-mediated disorders, and methods of treating IL-31-mediated disorders using such binding molecules.Also provided herein are binding molecules with an IL-31RA-antigen-binding domain capable of inhibiting IL-31 activity and an IL-13-antigen binding domain capable of inhibiting IL-13activity, compositions of such binding molecules for treating IL-31-mediated disorders and / or IL-13-mediated disorders,uses of such binding molecules as medicaments for treating IL-31-mediated disorders and / or IL-13-mediateddisorders, and methods of treating IL-31-mediated disorders and / or IL-13-mediated disorders using such binding molecules.

The present application relates to the technical fields of biological medicine and cellular immunotherapy, and particularly relates to a signal conversion receptor targeting IL-10, an engineered macrophage and application thereof. The signal conversion receptor is composed of an extracellular domain and a transmembrane domain and an intracellular domain derived from TLR9, and the extracellular domain sequentially comprises a signal peptide, a HA tag and a specific binding domain of an IL-10 receptor alpha subunit from N-terminal to C-terminal. The present application further prepares an engineered macrophage SR CAR-M capable of specifically recognizing IL-10 and converting it into a TLR9 activation signal, which can induce macrophages to polarize to M1 type and has excellent phagocytosis and killing capacity for bladder cancer, breast cancer, lung cancer and melanoma cells, and can be used for preparing related tumor treatment drugs, overcoming the common problems of existing cell therapy, such as easy exhaustion, difficult infiltration and easy inhibition in solid tumors, and having significant clinical transformation potential.

The present invention provides a polypeptide dimeric protein containing two monomers, each of which contains an extracellular domain (FcεRIa-ECD) of an alpha subunit of an IgE Fc receptor. The dimeric protein according to the present invention has advantages that an excellent binding ability to IgE is exhibited as compared with a conventional therapeutic agent containing an anti-IgE antibody, and less other side effects are exhibited due to lack of ADCC and CDC functions. Thus, the dimeric protein can be applied to a medical product for treating or preventing an IgE-mediated allergic disease.

An HSV vector comprising an expression cassette for one or more of IL12, IL15, and hIL15Receptor alpha subunit is provided.

The present disclosure provides a population of genetically modified immune cells and uses thereof, the modified immune cells comprising (i) a chimeric antigen receptor (CAR) targeting a target protein on a target cell; (ii) a first immunomodulatory fusion protein comprising an ectodomain derived from a protein of tumor necrosis factor (TNF) superfamily, and an endodomain derived from a costimulatory molecule of a TNF receptor superfamily protein; (iii) a second immunomodulatory fusion protein comprising an ectodomain derived from a protein of TNF receptor superfamily, and an endodomain derived from a common g-chain cytokine receptor; and (iv) a third immunomodulatory fusion protein comprising an ectodomain derived from the same TNF receptor superfamily protein as in the second immunomodulatory fusion protein, and an endodomain derived from an a or b receptor subunit of the common g-chain cytokine receptor family.

A series of subunit selective allosteric modulators of NMDA receptor function according to Formula (I) is provided herein. Also provided is a method of treating neurological disorders such as Alzheimer's disease Parkinson's disease, schizophrenia, depression, stroke, psychosis and the like using compounds of Formula (I), optionally in combination with one or more further active agent. Pharmaceutical compositions containing a compound of Formula (I) and optionally one or more active agent for treating such disorders may be provided in the form of a tablet, capsule, pill, gel, granules, aerosol, aqueous buffer or a nanoparticle formulation, emulsion, liposome, etc.

Conditionally active receptor agonists that, when activated, bind to IL-2 receptor βc heterodimer (IL-2Rβc), IL-4 receptor αcheterodimer (IL-4Rαc), or IL-13 receptor α subunit (IL-13Rα) are disclosed, as are components of the conditionally active receptor agonists and methods for using the conditionally active receptor agonists.

The present invention provides compounds of formula (I) and / or salt thereof and / or geometric isomer thereof and / or stereoisomer thereof and / or enantiomer thereof and / or racemate thereof and / or diastereomer thereof and / or biologically active metabolite thereof and / or prodrug thereof and / or solvate thereof and / or hydrate thereof and / or polymorph thereof having affinity and selectivity for the gamma-aminobutyric acid A receptor subunit alpha 5 and act as GABAA α5 negative allosteric modulators, thereby useful in the treatment or prevention of diseases related to the GABAA α5 receptor, process for the preparation thereof, pharmaceutical compositions comprising them alone or in combination with one or more other active ingredients and their use as medicaments.

Provided are antibodies and antigen binding fragments thereof that bind to human interleukin-11 receptor subunit α (IL-11Rα) and related compositions, which may be used in any of a variety of therapeutic or diagnostic methods, including the treatment or diagnosis of cancers, inflammatory diseases, autoimmune diseases, and others.

The present invention provides methods of treating thyroid eye disease (TED) by administering an antibody, or and an antigen-binding fragment thereof, that binds to human interleukin-11 receptor subunit alpha (IL-11R alpha).

Methods for treating thyroid eye disease (TED) are provided by administering an antibody or antigen-binding fragment thereof that binds to human interleukin-11 receptor subunit alpha (IL-11Rα).

Provided are binding molecules comprising at least one interleukin-31 (IL-31) receptor subunit alpha-antigen-binding domain (IL-31RA-antigen-binding domain) capable of inhibiting IL-31 activity and uses of such binding molecules as medicaments for treating IL-31-mediated disorders. Also provided herein are binding molecules with an IL-31RA-antigen-binding domain capable of inhibiting IL-31 activity, and an IL-31RA-antigen-binding domain capable of inhibiting IL-13 activity, as well as uses of such binding molecules as medicaments for treating IL-31-mediated disorders and / or IL-13-mediated disorders.

The invention discloses application of a signal sequence receptor subunit delta gene SSR4 as a drug target in development of lung adenocarcinoma treatment drugs. The invention further discloses an RNAi molecule for inhibiting the SSR4 gene to treat lung adenocarcinoma. The RNAi molecule is a shRNA molecule with a target sequence selected from SEQ ID NO: 1, SEQ ID NO: 4, SEQ ID NO: 7 and SEQ ID NO: 10. The shRNA molecule disclosed by the invention can be used for preparing a medicine for treating lung adenocarcinoma.

The application belongs to the field of biomedical technology, and aims to solve the problems of lack of metabolic typing characteristics in the current ESCC molecular typing method, lack of esophageal squamous cell carcinoma molecular typing method based on proteomics and metabolomics, and provides an esophageal squamous carcinoma ESCC molecular typing marker based on DIA proteomics and non-targeted metabolomics and its application. The marker is a combination of 4 proteins and 2 metabolites, the 4 proteins are: hexokinase 3 (HK3), Sec1 family domain protein 1 (SCFD1), septin 5 (SEPTIN5), and signal sequence receptor alpha subunit (SSR1); the 2 metabolites are creatine and 2-deoxy-D-glucose (2'DG). The application fills the gap of the molecular typing method based on proteomics and metabolomics in the field of esophageal squamous carcinoma research, and the proposed molecular typing model can be used as a method for diagnosis, treatment and prognosis evaluation of esophageal squamous carcinoma patients.

Described herein are the design and production of antibodies and antigen-binding fragments (e.g., chimeric and humanized antibodies) that specifically bind and inhibit activation of human common gamma chain (gamma c) (shared signaling receptor subunits used by six gamma c cytokines). Methods of production and functional assays that assess the efficacy of the produced antibodies are also described, along with the results that such anti-gammac antibodies are indicated for use in the treatment or prevention of autoimmune cases mediated by gammac or gammac cytokines, such as GVHD.

The present disclosure provides interleukin-13 receptor subunit alpha-2 antibody drug conjugate structures. The antibody-drug conjugate structures include a branched linker, where two or more payloads per branched linker are attached to an antibody. In addition, the disclosure also encompasses compounds and methods for production of such conjugates. In addition, the disclosure also encompasses methods of using the conjugates.

Engineered synthetic signal transduction molecules, referred to herein as "trikines," are provided. A trikine is a trispecific ligand of genetically engineered cell surface receptors, wherein the trikine specifically binds with high affinity to the extracellular domains of three different cell surface receptor polypeptides. In some embodiments, receptor multimerization resulting from binding to a trikine leads to intracellular transphosphorylation of the receptor subunits. In some embodiments, a trikine modulates STAT signal transduction resulting from receptor binding and multimerization.